Insulin-like growth factors (IGF) 1 and 2 stimulate the development and progression of different types of cancer. This animation helps to educate and inform about the various pathways associated with IGF 1 and 2, highlighting the mechanism behind a monoclonal antibody developed by Boehringer Ingelheim, which binds to and neutralises these ligands. Preclinical studies have shown that this particular antibody inhibits tumour cell proliferation and growth and may therefore be used to treat patients with cancer. The story-telling potential offered by the animation encourages increased engagement, utilizing spectacular imagery to emphasise the science behind the pharmaceutical product.